Alfasigma

Alfasigma is an Italian pharmaceutical company headquartered in Bologna. It was formed in 2015 through the combination of Alfa Wassermann and Sigma-Tau, bringing together established businesses in prescription medicines, specialty pharmaceuticals, and consumer healthcare. Its activities include gastrointestinal and hepatology medicines, vascular products, and other specialist therapies, as well as selected over-the-counter and health products. Alfasigma commercializes products through its own operations, manufacturing capabilities, and external commercial partnerships across international markets. Italy remains an important base for the company, while its business has also expanded into the United States and other overseas markets. Public sources generally describe Alfasigma as a privately held, family-controlled pharmaceutical company, and it has no publicly traded ticker. The supplied country was Spain, but reliable public information identifies the company and its headquarters with Italy; this entry has therefore corrected the country. Detailed information on current executives, market-by-market sales, and the complete product portfolio is not sufficiently verified here and has been left blank.

Alfasigma is built on the businesses of two Italian pharmaceutical companies, Alfa Wassermann and Sigma-Tau. Before the combination, both companies had established activities in prescription medicines, specialty therapies, and healthcare products. In 2015, they merged to create Alfasigma, with the aim of combining research, manufacturing, and commercial capabilities into a larger international Italian pharmaceutical group. The combined company continued to focus on gastrointestinal, hepatology, vascular, and other specialty areas, while retaining selected over-the-counter and consumer health activities. Alfasigma subsequently pursued international expansion through subsidiaries, licensing arrangements, and market development, with the United States becoming an important part of its international footprint. The company remains privately held and does not provide the same continuous public disclosure of quarterly financial results, sales volumes, and share-price data as a listed pharmaceutical company. Public information on annual operating performance, executive changes, and individual launch dates is not consistently complete, so this history includes only the developments that can be stated with reasonable confidence.

• 2015
  [1]Alfasigma official websitealfasigma.com

• Xifaxan

  Xifaxan is a prescription brand based on rifaximin and is associated with gastrointestinal treatment. It is one of the more recognizable products in Alfasigma's international business, although approved indications and commercial arrangements can vary by country.

• Normix

  Normix is a rifaximin brand used by Alfasigma in selected markets and belongs to its gastrointestinal medicines portfolio. Product naming, approved indications, and commercial ownership may differ across markets.

1. 1Alfasigma official websitealfasigma.com
2. 2Alfasigma corporate informationalfasigma.com